Mesa Buprenorphine Doctors

 

Feature Your Practice at the Top of This City Page

Locate Mesa buprenorphine and suboxone doctors who specialize in the treatment of opioid addiction.

Dr. Travis Clark Stiegler, D.O.
204 North Center Street
Mesa, AZ 85201
Main Tel: (480) 962-0868
 
 
Dr. Michel A. Sucher, M.D.
Community Bridges, Inc.
1855 W. Baseline Road, Suite 101
Mesa, AZ 85201
Main Tel: 480-990-3111
 
 
John S. Kingsley,
570 West Brown Road
Mesa, AZ 85201
Main Tel: (480) 344-2000
 
 
Daniel Kenneth Merrill, M.D.
570 West Brown
Mesa, AZ 85201
Main Tel: (480) 344-2000
 
 
Dana-Jean S. La Haie, M.D.
1440 South Country Club Drive
Suite #12
Mesa, AZ 85210
Main Tel: (480) 838-5550
 
 
Dr. Suzanne A. Sisley, M.D.
1220 South Alma School Road
Suite 206
Mesa, AZ 85210
Main Tel: 928-474-6617
 
 
Warren H. Tripp, Jr., M.D.
Future Family Medicine PLLC
1140 South San Jose, Suite B
Mesa, AZ 85202
Main Tel: (480) 833-1859
 
 
Amish S. Purohit, M.D.
Arizona Priority Care Plus
706 North McQueen Road, Suite 109
Gilbert, AZ 85233
Main Tel: (480) 800-6400
 
 
John S. Martin, M.D.
1501 North Gilbert Road
Suite 200
Gilbert, AZ 85234
Main Tel: (480) 728-4430
 
 
Dr. Joshua Adam Levy, D.O.
81 West Guadalupe Road
Suite 111
Gilbert, AZ 85233
Main Tel: (480) 366-4490
 
 
J. Carvel Jackson, D.O.
3048 E Baseline Road
suite 122
Mesa, AZ 85204
Main Tel: (480) 737-1955
 
 

Sublocade Now Available

Sublocade is a newly released medication alternative for treating opioid addiction. It is a product of Indivior, the pharmaceutical company responsible for Suboxone. Sublocade is a once monthly injection of time-released buprenorphine typically provided to patients who have been receiving buprenorphine for at least (7) days and who are stable on their medication. The injection Read More

Posted in Buprenorphine, Medication-Assisted Treatment | Tagged | Leave a comment

Ohio Increases Buprenorphine Access

In 2017, Ohio increased its number of buprenorphine-approved prescribers by 266. This was the result of a $2.3 million dollar Federal grant that provided state-wide training to doctors, nurse practitioners, and physician assistants as reported by Cleveland.com. Historically, Ohio had numerous communities that were underserved with 19 counties having no buprenorphine providers at the beginning Read More

Posted in Addiction Medications, Buprenorphine, Medication-Assisted Treatment, Suboxone | Tagged , | Leave a comment

The Drug Treatment Act of 2000 permitted doctors who meet certain training qualifications to prescribe buprenorphine in the treatment of heroin addiction and other opioid addictions. Buprenorphine physicians became able to assist opioid addicted patients in an office setting bypassing the restrictions that typically apply to patients receiving methadone. This treatment method maximized patient convenience and accessibility thus increasing the number of people who could access medication-assisted treatment (MAT) for opioid addiction.

Buprenorphine is the medication ingredient in Suboxone, Subutex, Zubsolv, Bunavail, and Probuphine that specifically targets opioid withdrawal. Buprenorphine, or "Bup", is the leading pharmaceutical treatment (alongside methadone) for addressing opioid addiction. Both medications are in widescale use throughout the world due to their efficacy in removing the persistent discomfort associated with withdrawal from opiates (ex. runny nose, body ache, anxiety, nausea, diarrhea and other symptoms).

Buprenorphine.US is an information resource for people in search of doctors who specialize in treating opioid addiction with buprenorphine. In recent years, individuals from all age groups and backgrounds have suffered with an unexpected opioid dependency that negatively affected their family relationships, job, finances, and self-esteem. Addiction is a relentless illness, and persistent opiate withdrawal is a particularly difficult medical dilemma. There are presently thousands of U.S. physicians seeking to assist patients ready to address their opioid addiction. Buprenorphine.US is a tool for connecting buprenorphine doctors with new prospective patients wanting specialized primary care for their addictive disorder.